leadf
logo-loader
viewCytoDyn Inc.
(
OTCQB:CYDY
)

CytoDyn receives order from Chiral Pharma to use Vyrologix on COVID-19 patients in the Philippines

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive that Chiral Pharma Corporation placed its first purchase order for its drug Vyrologix under a compassionate special permit to treat critically ill coronavirus patients in the Philippines.

Pourhassan says the Vancouver, Washington-based late-stage biotech will earn revenue after order fulfillment and the terms of the agreement are ironed out.

A portion of this interview was edited for accuracy.

Quick facts: CytoDyn Inc.

Follow
OTCQB:CYDY

Price: 2.285 USD

Market Cap: $1.44 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn says Brazil has approved a Phase 3 trial of its drug in critically...

CytoDyn Inc's Nader Pourhassan tells Proactive that Brazil’s regulatory authority Agência Nacional de Vigilância Sanitária (ANVISA) has approved the start of an additional Phase 3 CD16 clinical trial of its flagship drug leronlimab to treat critically ill coronavirus patients. Pourhassan says...

5 days, 4 hours ago

2 min read